# eIF4G siRNA (m): sc-35287



The Power to Question

## **BACKGROUND**

The initiation of protein synthesis in eukaryotic cells is regulated by interactions between protein initiation factors and RNA molecules. The eukaryotic initiation complex elF4F exists *in vitro* as a trimeric complex of elF4G, elF4E, and elF4A. Together, the complex allows ribosome binding to mRNA by inducing the unwinding of mRNA secondary structures. elF4E binds to the mRNA "cap" during an early step in the initiation of protein synthesis. elF4A acts as an ATP-dependent RNA helicase. elF4G acts as a bridge between elF4E, elF4A, and the elF3 complex.

## **REFERENCES**

- Rychlik, W., et al. 1987. Amino acid sequence of the mRNA cap-binding protein from human tissues. Proc. Natl. Acad. Sci. USA 84: 945-949.
- Reddy, N.S., et al. 1988. Isolation and mapping of a gene for protein synthesis initiation factor 4A and its expression during differentiation of murine erythroleukemia cells. Gene 70: 231-243.
- Rozen, F., et al. 1990. Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F. Mol. Cell. Biol. 10: 1134-1144.
- Jaramillo, M., et al. 1991. RNA unwinding in translation: assembly of helicase complex intermediates comprising eukaryotic initiation factors elF-4F and elF-4B. Mol. Cell. Biol. 11: 5992-5997.
- 5. Scheper, G.C., et al. 1992. Eukaryotic initiation factors-4E and -4F stimulate 5' cap-dependent as well as internal initiation of protein synthesis. J. Biol. Chem. 267: 7269-7274.
- Yan, R., et al. 1992. Amino acid sequence of the human protein synthesis initiation factor eIF-4 γ. J. Biol. Chem. 267: 23226-23231.
- 7. Merrick, W.C. 1994. Eukaryotic protein synthesis: an *in vitro* analysis. Biochimie 76: 822-830.
- Lamphear, B.J., et al. 1995. Mapping of functional domains in eukaryotic protein synthesis initiation factor 4G (eIF4G) with picornaviral proteases. Implications for cap-dependent and cap-independent translational initiation. J. Biol. Chem. 270: 21975-21983.

## **CHROMOSOMAL LOCATION**

Genetic locus: Eif4g1 (mouse) mapping to 16 B1.

## **PRODUCT**

elF4G siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu$ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see elF4G shRNA Plasmid (m): sc-35287-SH and elF4G shRNA (m) Lentiviral Particles: sc-35287-V as alternate gene silencing products.

For independent verification of eIF4G (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-35287A, sc-35287B and sc-35287C.

#### STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNAse-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

## **APPLICATIONS**

eIF4G siRNA (m) is recommended for the inhibition of eIF4G expression in mouse cells.

#### **SUPPORT REAGENTS**

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

## **GENE EXPRESSION MONITORING**

eIF4G (A-10): sc-133155 is recommended as a control antibody for monitoring of eIF4G gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG $\kappa$  BP-HRP: sc-516102 or m-lgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>TM</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG $\kappa$  BP-FITC: sc-516140 or m-lgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850.

## **RT-PCR REAGENTS**

Semi-quantitative RT-PCR may be performed to monitor eIF4G gene expression knockdown using RT-PCR Primer: eIF4G (m)-PR: sc-35287-PR (20  $\mu$ l, 563 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

## **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.